GERD & acid-related disorders

What changes during this transition

GERD is a defined clinical disease — gastroesophageal reflux disease per the ACG 2022 guidelines — characterized by symptomatic and/or mucosal injury from retrograde flow of gastric contents across an incompetent lower esophageal sphincter. Roughly 20% of US adults experience weekly symptoms; the disease spans non-erosive reflux disease (NERD), erosive esophagitis (LA grades A–D), Barrett's esophagus (with its esophageal-adenocarcinoma surveillance implications), peptic ulcer disease, and the increasingly recognized adjacent pathology of eosinophilic esophagitis (EoE — distinct disease, often presents with GERD-like symptoms, requires endoscopy plus biopsy to differentiate). Standard-of-care is well-established and deep. PPI therapy (omeprazole, esomeprazole, pantoprazole, lansoprazole, rabeprazole) has been Tier 1 for symptomatic and erosive GERD since the late 1980s, with an 8-week trial at standard dose as the diagnostic-therapeutic standard; step-down to lowest effective dose or on-demand dosing is the chronic-care goal. H2 blockers (famotidine; ranitidine was withdrawn 2020 over NDMA contamination) sit as adjuncts, step-down options, and breakthrough management. Antacids (calcium carbonate, magnesium hydroxide, aluminum hydroxide) cover episodic breakthrough. Lifestyle modification carries trial-backed weight: head-of-bed elevation, weight loss (the single biggest lifestyle lever), avoidance of late meals, trigger-food identification, smoking cessation, and alcohol moderation. Helicobacter pylori test-and-treat is part of the workup. Endoscopy is indicated for alarm features — dysphagia, odynophagia, GI bleeding, iron-deficiency anemia, unintended weight loss, vomiting, age >60 with new-onset symptoms — and for Barrett's surveillance. Refractory GERD on optimized PPI moves to specialist workup (pH-impedance monitoring, manometry) and surgical evaluation; Nissen fundoplication is the standard-of-care surgical option, with magnetic sphincter augmentation (LINX) and transoral incisionless fundoplication (TIF) as newer alternatives. The long-term considerations of chronic acid suppression matter editorially because the patient population is enormous and the clinical-care under-monitoring of those considerations is well-documented. PPI use beyond 2 years is associated with B12 deficiency (Lam 2013 JAMA, 65% increased odds), magnesium deficiency (FDA safety communication 2011), increased fracture risk (FDA labeling 2010), increased C. difficile infection risk, community-acquired pneumonia signal, and a documented rebound hypersecretion phenomenon on abrupt discontinuation. None of these is a reason to stop a clearly indicated PPI in a patient with erosive esophagitis or Barrett's, but they ARE reasons to reassess ongoing necessity at the 2-year mark, step down where clinically appropriate, and monitor B12 and magnesium proactively. The library's surfaced peptide cases on this axis are narrow and editorially deliberate. BPC-157 carries the most paradoxical case in the entire substrate program — gastric mucosal protection is the foundational Sikiric research domain, the compound is literally named Body Protective Compound and was characterized in gastric-juice fractions, and the NSAID-induced / ethanol-induced / stress-induced gastric ulceration rodent literature is the corpus the compound's name and reputation were built on. This is closer to BPC's actual labeled research focus than ANY other indication in the Juno library — closer than functional-GI, closer than wound-healing, closer than tendinopathy. The editorial register has to shift to 'foundational research domain' for this trigger. And yet: zero published human GERD RCT, zero erosive-esophagitis RCT, zero peptic-ulcer RCT. The human translation that should have been easiest is still absent. B12-methylcobalamin is surfaced as the maintenance-of-care precondition in chronic-PPI users — not a GERD treatment but the iatrogenic-deficiency catch that the Lam 2013 evidence base supports, with the multi-jurisdictional clinical role for methylcobalamin (Japan and adjacent jurisdictions as registered medicine) backing the bioactive-form preference. What is NOT surfaced as a discovery card is editorially deliberate. KPV is substrate-only — the community framing connects to eosinophilic esophagitis via α-MSH anti-inflammatory mechanism, and while EoE is a real and rising acid-related-adjacent pathology, dupilumab (Dupixent, FDA-approved May 2022 for EoE) and oral budesonide (Eohilia, FDA-approved February 2024) are the paradigm-shifting interventions in that space. Larazotide is substrate-only — the 'leaky gut + GERD' framing is mechanism-misaligned with GERD pathophysiology (LES dysfunction + acid exposure, not enterocyte tight-junction modulation), and the celiac Phase 3 program at 9 Meters Biopharma was contested in 2022–2023. Thymosin α-1 is substrate-only — the immune-modulation framing for 'chronic GERD inflammation' is mechanism-misaligned, Rule 6 keeps HBV/HCV/sepsis evidence from propagating, and the autoimmune-overlap subset makes Th1-augmentation directionally wrong.